SA writer David Zanoni recommends having a look at Celgene (CELG -1.5%), citing its 5...

SA writer David Zanoni recommends having a look at Celgene (CELG -1.5%), citing its 5 FDA-approved cancer drugs and its extensive pipeline. What Zanoni really likes, though, is Celgene's earnings growth, which is forecast at an average of 25% over the next five years. If that is achieved, "Celgene's stock price of (about) $65 should grow to around $200."

From other sites
Comments (2)
  • petten
    , contributor
    Comments (121) | Send Message
    yeah right. celg has been around its current price for more than five years. dream on.
    11 Jun 2012, 04:23 PM Reply Like
  • Brendan O'Boyle
    , contributor
    Comments (1290) | Send Message
    I have to look over what CELG has in the pipeline. 300% seems unlikely, CELG's current market cap is 27B, so 3x would be nearly 80% of the largest Pharma companies (MRK, PFE, etc.).


    I can't see how that can happen without CELG tripling revenues, which probably means at least doubling their drugs. They have five, five more soon is unlikely.


    I think CELG is a good buy, just don't expect a 300% return.
    14 Jun 2012, 01:17 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs